NCT07144228
Validation of a Platelet Proteomic Assay for Diagnosing and Monitoring Prostate Cancer
At risk: Primary completion moved 12 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 4 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Sep 30, 2026 to Sep 30, 2027
- Eligibility criteria expanded, about 6 words
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Dec 15, 2025 to Mar 11, 2026
- Notable Start date: Aug 20, 2025 to Dec 15, 2025v2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Levels of HeLP™ proteins in the platelets of patients suspected to have PCa
Timeframe: Baseline
Diagnostic accuracy as reported by area under the curve (AUC)
Timeframe: Baseline
Arms and interventions
Control Group
Researchers are screening men who are suspicious of Pca, so those who will be negative for cancer will be the control group.
Case Group
Researchers are screening men who are suspicious of Pca, so those who will be diagnosed will be the case group.
Devices: HeLP TM
Sites
1 site in 1 country
- Duke UniversityDurham, North Carolina, United States